Cancer Research and Treatment

Joong-Bae Ahn

2 Articles

Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea: Min Hee Hong, Hyo Song Kim, Chan Kim, Jung Ryun Ahn, Hong Jae Chon, Sang-Joon Shin, Joong-Bae Ahn, Hyun Cheol Chung, Sun Young Rha; Cancer Res Treat. 2009;41(2):67-72. Published online June 30, 2009; DOI: https://doi.org/10.4143/crt.2009.41.2.67

Purpose

The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC).

Materials and Methods

Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment.

Results

Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progression-free survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients (18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients had discontinued treatment. Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia (69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-foot syndrome (9.2%).

Conclusion

Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study.

Citations

Citations to this article as recorded by

pH-Responsive Block Copolymer Micelles of Temsirolimus: Preparation, Characterization and Antitumor Activity Evaluation
Ling Wang, Fangqing Cai, Yixuan Li, Xiaolan Lin, Yuting Wang, Weijie Liang, Caiyu Liu, Cunze Wang, Junshan Ruan
International Journal of Nanomedicine.2024; Volume 19: 9821. CrossRef
Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis
Amit Joshi, Ishan Patel, Pratiksha Kapse, Manmohan Singh
Kidney Cancer.2022; 6(1): 37. CrossRef
High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma
Yun Beom Sang, Hannah Yang, Won Suk Lee, Seung Joon Lee, Seul-Gi Kim, Jaekyung Cheon, Beodeul Kang, Chang Woo Kim, Hong Jae Chon, Chan Kim
Cancers.2022; 14(23): 5985. CrossRef
Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma
Dongrul Shin, Chang Wook Jeong, Cheryn Song, Minyong Kang, Seong Il Seo, Jung Kwon Kim, Hakmin Lee, Jinsoo Chung, Sung-Hoo Hong, Eu Chang Hwang, Cheol Kwak, Jae Young Park
Medicine.2021; 100(31): e26826. CrossRef
Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
Ahmed Badran, Mahmoud A. Elshenawy, Amgad Shahin, Ali Aljubran, Ahmed Alzahrani, Abdelmoneim Eldali, Shouki Bazarbashi
JCO Global Oncology.2020; (6): 19. CrossRef
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
Motohide Uemura, Yoshihiko Tomita, Hideaki Miyake, Shingo Hatakeyama, Hiro‐omi Kanayama, Kazuyuki Numakura, Toshio Takagi, Tomoyuki Kato, Masatoshi Eto, Wataru Obara, Hirotsugu Uemura, Toni K. Choueiri, Robert J. Motzer, Yosuke Fujii, Yoichi Kamei, Yoshik
Cancer Science.2020; 111(3): 907. CrossRef
First-Line Axitinib Versus Sorafenib in Asian Patients with Metastatic Renal Cell Carcinoma: Exploratory Subgroup Analyses of Phase III Data
Xinan Sheng, Feng Bi, Xiubao Ren, Ying Cheng, Jinwan Wang, Brad Rosbrook, Ming Jiang, Jun Guo
Future Oncology.2019; 15(1): 53. CrossRef
The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics
Hiu Ting Chan, Yoon Ming Chin, Siew-Kee Low
Oncology and Therapy.2019; 7(1): 1. CrossRef
Risk of fatal adverse events in cancer patients treated with sunitinib
Bin Zhao, Hong Zhao, Jiaxin Zhao
Critical Reviews in Oncology/Hematology.2019; 137: 115. CrossRef
Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
Cancer Research and Treatment.2019; 51(4): 1578. CrossRef
Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients
Claudia Arena, Giuseppe Troiano, Alfredo De Lillo, Nunzio F. Testa, Lorenzo Lo Muzio
BioMed Research International.2018; 2018: 1. CrossRef
Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma
Nahjatul Kursyiah Abd Ghafar, Adlinda Alip, Teng Aik Ong, Ning Yi Yap, Marniza Saad
Journal of Cancer Research and Therapeutics.2018; 14(6): 1303. CrossRef
Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis
Xiaoyan Liu, Marta Fiocco, Jesse J. Swen, Henk-Jan Guchelaar
Acta Oncologica.2017; 56(4): 582. CrossRef
Oncogenic miR-100-5p is associated with cellular viability, migration and apoptosis in renal cell carcinoma
Peijie Chen, Canbin Lin, Jing Quan, Yulin Lai, Tao He, Liang Zhou, Xiang Pan, Xueling Wu, Yong Wang, Liangchao Ni, Shangqi Yang, Tao Wang, Yongqing Lai
Molecular Medicine Reports.2017; 16(4): 5023. CrossRef
miR‑660‑5p is associated with cell migration, invasion, proliferation and apoptosis in renal cell carcinoma
Tao He, Peijie Chen, Lu Jin, Jia Hu, Yifan Li, Liang Zhou, Shangqi Yang, Xiangming Mao, Yaoting Gui, Yun Chen, Yongqing Lai
Molecular Medicine Reports.2017;[Epub] CrossRef
Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma
Krisztián Nagyiványi, Barna Budai, Krisztina Bíró, Fruzsina Gyergyay, László Noszek, Zsófia Küronya, Hajnalka Németh, Péter Nagy, Lajos Géczi
Clinical Genitourinary Cancer.2016; 14(4): 314. CrossRef
BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen
Jung-woo Chae, Yi Ling Teo, Han Kiat Ho, Jaeyeon Lee, Hyun-moon Back, Hwi-yeol Yun, Mats O. Karlsson, Kwang-il Kwon, Alexandre Chan
Cancer Chemotherapy and Pharmacology.2016; 78(3): 623. CrossRef
Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study
Yoshihiko Tomita, Satoshi Fukasawa, Mototsugu Oya, Hirotsugu Uemura, Nobuo Shinohara, Tomonori Habuchi, Brian I. Rini, Ying Chen, Angel H. Bair, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza
Japanese Journal of Clinical Oncology.2016; 46(11): 1031. CrossRef
Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction
Siew-Kee Low, Koya Fukunaga, Atsushi Takahashi, Koichi Matsuda, Fumiya Hongo, Hiroyuki Nakanishi, Hiroshi Kitamura, Takamitsu Inoue, Yoichiro Kato, Yoshihiko Tomita, Satoshi Fukasawa, Tomoaki Tanaka, Kazuo Nishimura, Hirotsugu Uemura, Isao Hara, Masato Fu
PLOS ONE.2016; 11(2): e0148177. CrossRef
Sunitinib therapy for metastatic renal cell carcinoma: A urologist’s perspective
M Darrad, R Wilson
Journal of Clinical Urology.2016; 9(1): 32. CrossRef
Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience
Rafael Corrêa Coelho, Tomás Reinert, Franz Campos, Fábio Affonso Peixoto, Carlos Augusto de Andrade, Thalita Castro, Daniel Herchenhorn
International braz j urol.2016; 42(4): 694. CrossRef
Tumor suppressor miR-149-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma
LU JIN, YIFAN LI, JIAJU LIU, SHANGQI YANG, YAOTING GUI, XIANGMING MAO, GUOHUI NIE, YONGQING LAI
Molecular Medicine Reports.2016; 13(6): 5386. CrossRef
Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore
Hui Shan Tan, Huihua Li, Yu Wen Hong, Chee-Keong Toh, Alvin Wong, Gilberto Lopes, Miah Hiang Tay, Alexandre Chan, Xin Yao, Tiffany Tang, Quan Sing Ng, Ravindran Kanesvaran, Noan Minh Chau, Min-Han Tan
Clinical Genitourinary Cancer.2015; 13(4): e285. CrossRef
Central and Eastern European Experience with Sunitinib in Metastatic Renal Cell Carcinoma: A Sub-analysis of the Global Expanded-Access Trial
Eduard Vrdoljak, Lajos Géczi, Jozef Mardiak, Tudor-Eliade Ciuleanu, Sophie Leyman, Ke Zhang, Peter Sajben, Laszlo Torday
Pathology & Oncology Research.2015; 21(3): 775. CrossRef
Axitinib plasma pharmacokinetics and ethnic differences
Ying Chen, Akiyuki Suzuki, Michael A. Tortorici, May Garrett, Robert R. LaBadie, Yoshiko Umeyama, Yazdi K. Pithavala
Investigational New Drugs.2015; 33(2): 521. CrossRef
Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors
Tomohiro Terada, Satoshi Noda, Ken-ichi Inui
Pharmacology & Therapeutics.2015; 152: 125. CrossRef
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial
J.L. Lee, M.K. Kim, I. Park, J.-H. Ahn, D.H. Lee, H.M. Ryoo, C. Song, B. Hong, J.H. Hong, H. Ahn
Annals of Oncology.2015; 26(11): 2300. CrossRef
Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer
Naomi Kiyota, Martin Schlumberger, Kei Muro, Yuichi Ando, Shunji Takahashi, Yasukazu Kawai, Lori Wirth, Bruce Robinson, Steven Sherman, Takuya Suzuki, Katsuki Fujino, Anubha Gupta, Seiichi Hayato, Makoto Tahara
Cancer Science.2015; 106(12): 1714. CrossRef
Efficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt
Wael Abdelgawad Edesa, Raafat Ragaey Abdelmalek
Asian Pacific Journal of Cancer Prevention.2015; 16(5): 1971. CrossRef
Induction of apoptotic cell death by betulin in multidrug-resistant human renal carcinoma cells
NAM-HUI YIM, YOUNG PIL JUNG, AEYUNG KIM, TAESOO KIM, JIN YEUL MA
Oncology Reports.2015; 34(2): 1058. CrossRef
Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
Y Wang, T K Choueiri, J-L Lee, M-H Tan, S Y Rha, S A North, C K Kollmannsberger, D F McDermott, D Y C Heng
British Journal of Cancer.2014; 110(6): 1433. CrossRef
The Effect of ABCG2 Genotype on the Population Pharmacokinetics of Sunitinib in Patients With Renal Cell Carcinoma
Tomoyuki Mizuno, Masahide Fukudo, Tsuyoshi Fukuda, Tomohiro Terada, Min Dong, Tomomi Kamba, Toshinari Yamasaki, Osamu Ogawa, Toshiya Katsura, Ken-ichi Inui, Alexander A. Vinks, Kazuo Matsubara
Therapeutic Drug Monitoring.2014; 36(3): 310. CrossRef
Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
Ibrahim Yildiz, Fatma Sen, Leyla Kilic, Rumeysa Ciftci, Mert Basaran
Korean Journal of Urology.2014; 55(1): 74. CrossRef
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries
Camillo Porta, Antonin Levy, Robert Hawkins, Daniel Castellano, Joaquim Bellmunt, Paul Nathan, Ray McDermott, John Wagstaff, Paul Donnellan, John McCaffrey, Francis Vekeman, Maureen P. Neary, Jose Diaz, Faisal Mehmud, Mei Sheng Duh
Cancer Medicine.2014; 3(6): 1517. CrossRef
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
WILLIAM K. OH, DAVID McDERMOTT, CAMILLO PORTA, ANTONIN LEVY, REZA ELAIDI, FLORIAN SCOTTE, ROBERT HAWKINS, DANIEL CASTELLANO, JOAQUIM BELLMUNT, SUN YOUNG RHA, JONG-MU SUN, PAUL NATHAN, BRUCE A. FEINBERG, JEFFREY SCOTT, RAY McDERMOTT, JIN-HEE AHN, JOHN WAGS
International Journal of Oncology.2014; 44(1): 5. CrossRef
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
R J Motzer, B Escudier, R Bukowski, B I Rini, T E Hutson, C H Barrios, X Lin, K Fly, E Matczak, M E Gore
British Journal of Cancer.2013; 108(12): 2470. CrossRef
Therapy management with sunitinib in patients with metastatic renal cell carcinoma: Key concepts and the impact of clinical biomarkers
Daniel Castellano, Alain Ravaud, Manuela Schmidinger, Guillermo De Velasco, Federico Vazquez
Cancer Treatment Reviews.2013; 39(3): 230. CrossRef
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
Hye Ryun Kim, Hyung Soon Park, Woo Sun Kwon, Ji Hyun Lee, Yusuke Tanigawara, Sun Min Lim, Hyo Song Kim, Sang Jun Shin, Jung Bae Ahn, Sun Young Rha
Cancer Chemotherapy and Pharmacology.2013; 72(4): 825. CrossRef
Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib
Whi-An Kwon, In-Chang Cho, Ami Yu, Byung-Ho Nam, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Annals of Surgical Oncology.2013; 20(13): 4397. CrossRef
Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma
Ki Hyang Kim, Sang Hyun Yoon, Hae-Jung Lee, Hyo Song Kim, Sang Joon Shin, Joong Bae Ahn, Sun Young Rha
Cancer Chemotherapy and Pharmacology.2013; 72(4): 853. CrossRef
Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain
Daniel Castellano, Mei Sheng Duh, Caroline Korves, Ellison Dial Suthoff, Maureen Neary, Luis Javier Hernández Pastor, Joaquim Bellmunt
Expert Opinion on Drug Safety.2013; 12(4): 455. CrossRef
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib
Aiping Zhou, Wen Zhang, Chunxiao Chang, Xiaoyan Chen, Dafang Zhong, Qiong Qin, Donghua Lou, Haoyuan Jiang, Jinwan Wang
Cancer Chemotherapy and Pharmacology.2013; 72(5): 1043. CrossRef
Analysis of the Reasons for Dose Reduction or Discontinuation of Sunitinib in Korean Patients
노지혜, 이주연, 이혜숙, 김향숙, 강래영, 이용화
Journal of Korean Society of Health-System Pharmacists.2013; 30(3): 210. CrossRef
Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Pharmacokinetics of Sunitinib in Rats
Sachiko Kunimatsu, Tomoyuki Mizuno, Masahide Fukudo, Toshiya Katsura
Drug Metabolism and Disposition.2013; 41(8): 1592. CrossRef
Famitinib in metastatic renal cell carcinoma: a single center study
Wen ZHANG, Ai-Ping ZHOU, Qiong QIN, Chun-Xiao CHANG, Hao-Yuan JIANG, Jian-Hui MA, Jin-Wan WANG
Chinese Medical Journal.2013; 126(22): 4277. CrossRef
Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience
Aiping ZHOU
Asia-Pacific Journal of Clinical Oncology.2012; 8(2): 132. CrossRef
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients
Dok Hyun Yoon, Min-Hee Ryu, Baek-Yeol Ryoo, Moyeol Beck, Dae Ro Choi, Yoojin Cho, Jae-Lyun Lee, Heung-Moon Chang, Tae Won Kim, Yoon-Koo Kang
Investigational New Drugs.2012; 30(2): 819. CrossRef
Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
In-Chang Cho, Jinsoo Chung
Korean Journal of Urology.2012; 53(4): 217. CrossRef
Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics
Tomoyuki Mizuno, Masahide Fukudo, Tomohiro Terada, Tomomi Kamba, Eijiro Nakamura, Osamu Ogawa, Ken-ichi Inui, Toshiya Katsura
Drug Metabolism and Pharmacokinetics.2012; 27(6): 631. CrossRef
Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey
I. Yildiz, F. Sen, M. Basaran, M. Ekenel, F. Agaoglu, E. Darendeliler, H. M. Tunc, F. Ozcan, S. Bavbek
Japanese Journal of Clinical Oncology.2011; 41(12): 1380. CrossRef
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
Yoshihiko Tomita, Hirotsugu Uemura, Hiroyuki Fujimoto, Hiro-omi Kanayama, Nobuo Shinohara, Hayakazu Nakazawa, Keiji Imai, Yoshiko Umeyama, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza
European Journal of Cancer.2011; 47(17): 2592. CrossRef
Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience
Eugene Hwang, Hyo Jin Lee, Chong Koo Sul, Jae Sung Lim
Korean Journal of Urology.2010; 51(7): 450. CrossRef
Kidney Cancer Working Group Report
S. Naito, Y. Tomita, S. Y. Rha, H. Uemura, M. Oya, H. Z. Song, L. H. Zhong, M. I. B. A. Wahid
Japanese Journal of Clinical Oncology.2010; 40(Supplement): i51. CrossRef
Hematologic Toxicity in Patients Treated with Sunitinib for Advanced Thyroid Cancer
Anastasios Gkountouvas, Ifigeneia Kostoglou-Athanassiou, Eirini Veniou, Panagiotis Repousis, Nikolaos Ziras, Philippos Kaldrimidis
Thyroid.2010; 20(6): 597. CrossRef
The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction
C. Yoo, J. E. Kim, J.-L. Lee, J.-H. Ahn, D. H. Lee, J.-S. Lee, S. Na, C.-S. Kim, J. H. Hong, B. Hong, C. Song, H. Ahn
Japanese Journal of Clinical Oncology.2010; 40(10): 980. CrossRef
Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis
Sang Hyun Yoon, Ki Hyang Kim, Junjeong Choi, Gun Min Kim, Joo Hoon Kim, Hyo Song Kim, Young Nyun Park, Sun Young Rha
Cancer Research and Treatment.2010; 42(3): 180. CrossRef
Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea
Jee Han Lee, Sung-Goo Chang, Seung Hyun Jeon, Gyeong Eun Min, Koo Han Yoo
Korean Journal of Urology.2010; 51(6): 379. CrossRef

12,943 View
74 Download
57 Crossref

Single Immunochemical Fecal Occult Blood Test for Detection of Colorectal Neoplasia: Dae Kyung Sohn, Seung-Yong Jeong, Hyo Seong Choi, Seok-Byung Lim, Jin Myeong Huh, Dae-Hyun Kim, Dae Yong Kim, Young Hoon Kim, Hee Jin Chang, Kyung Hae Jung, Joong-Bae Ahn, Hyun Kyung Kim, Jae-Gahb Park; Cancer Res Treat. 2005;37(1):20-23. Published online February 28, 2005; DOI: https://doi.org/10.4143/crt.2005.37.1.20

Abstract PDF PubReader ePub

Purpose

This study was designed to investigate the validity of a single immunochemical fecal occult blood test (FOBT) for detection of colorectal neoplasia.

Materials and Methods

A total of 3,794 average-risk screenees and 304 colorectal cancer patients admitted to the National Cancer Center, Korea, between May 2001 and November 2002, were studied prospectively. All screenees and admitted patients underwent FOBT and total colonoscopic examinations. Stools were self-collected, and examined using an immunochemical fecal occult blood test (OC-hemodia®, Eiken Chemical Co. Tokyo, Japan) and an OC-sensor analyzer® (Eiken Chemical Co. Tokyo, Japan).

Results

Of the 3,794 asymptomatic screenees, the colonoscopy identified colorectal adenomas and cancers in 613 (16.2%) and 12 (0.3%) subjects, respectively. The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The false positive rate of FOBT for colorectal cancer in screenees was 1.19%. For the total 316 colorectal cancer cases (including 12 cases from screenees), the FOBT sensitivities according to the T-stage were 38.5, 75.0%, 78.9 and 79.2% for T1, 2, 3 and 4 cancers, respectively. The sensitivities according to the Dukes stages A, B and C were 63.4, 79.3 and 78.6%, respectively.

Conclusion

The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The sensitivities of FOBT were about 80% for Dukes B or C colorectal cancers and 63.4% for Dukes A.

Citations

Citations to this article as recorded by

Interval Advanced Adenomas and Neoplasia in Patients with Negative Colonoscopy Following Positive Stool-Based Colorectal Cancer Screening Test
Kyle S. Liu, Rollin George, Caleb Shin, Jia Q. Xiong, Taher Jamali, Yan Liu, Priya Roy, Sonia Singh, Samuel Ma, Hashem B. El-Serag, Mimi C. Tan
Digestive Diseases and Sciences.2025; 70(1): 350. CrossRef
Findings in the distal and proximal colon in colonoscopy screening after positive FIT and related pre-procedure factors
M.� Henar Núñez Rodríguez, Pilar Díez Redondo, Fausto Riu Pons, Marta Cimavilla, Andrea Loza, Manuel Perez-Miranda
Revista Española de Enfermedades Digestivas.2022;[Epub] CrossRef
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals
Esmée J Grobbee, Pieter HA Wisse, Eline H Schreuders, Aafke van Roon, Leonie van Dam, Ann G Zauber, Iris Lansdorp-Vogelaar, Wichor Bramer, Sarah Berhane, Jonathan J Deeks, Ewout W Steyerberg, Monique E van Leerdam, Manon CW Spaander, Ernst J Kuipers
Cochrane Database of Systematic Reviews.2022;[Epub] CrossRef
Potential Modifiers and Different Cut-offs in Diagnostic Accuracy of Fecal Immunochemical Test in Detecting Advanced Colon Neoplasia: A Diagnostic Test Accuracy Meta-analysis
Mohammad Yaghoobi, Parsa Mehraban Far, Lawrence Mbuagbaw, Yuhong Yuan, David Armstrong, Lehana Thabane, Paul Moayyedi
Middle East Journal of Digestive Diseases.2022; 14(4): 382. CrossRef
Guidelines for accreditation of endoscopy units: quality measures from the Korean Society of Coloproctology
Rumi Shin, Seongdae Lee, Kyung-Su Han, Dae Kyung Sohn, Sang Hui Moon, Dong Hyun Choi, Bong-Hyeon Kye, Hae-Jung Son, Sun Il Lee, Sumin Si, Won-Kyung Kang
Annals of Surgical Treatment and Research.2021; 100(3): 154. CrossRef
Screening for Colorectal Cancer
Jennifer S. Lin, Leslie A. Perdue, Nora B. Henrikson, Sarah I. Bean, Paula R. Blasi
JAMA.2021; 325(19): 1978. CrossRef
Colorectal Cancer Screening Outcomes of 2412 Prostate Cancer Patients Considered for Carbon Ion Radiotherapy
Nao Kobayashi, Takahiro Oike, Nobuteru Kubo, Yuhei Miyasaka, Tatsuji Mizukami, Hiro Sato, Akiko Adachi, Hiroyuki Katoh, Hidemasa Kawamura, Tatsuya Ohno
Cancers.2021; 13(17): 4481. CrossRef
Evaluation of the Cut-Off Value of Fecal Immunochemical Test for Colorectal Cancer Screening during Health Checkups
Hye-Ran Park, Eun-Hee Nah, Jong-Seon Lee, Seon Cho
Journal of Laboratory Medicine and Quality Assurance.2021; 43(4): 190. CrossRef
Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis
Tobias Niedermaier, Yesilda Balavarca, Hermann Brenner
American Journal of Gastroenterology.2020; 115(1): 56. CrossRef
Sensitivity of Fecal Immunochemical Test for Colorectal Cancer Detection Differs According to Stage and Location
Tobias Niedermaier, Kaja Tikk, Anton Gies, Stefanie Bieck, Hermann Brenner
Clinical Gastroenterology and Hepatology.2020; 18(13): 2920. CrossRef
Performance Characteristics of Fecal Immunochemical Tests for Colorectal Cancer and Advanced Adenomatous Polyps
Thomas F. Imperiale, Rachel N. Gruber, Timothy E. Stump, Thomas W. Emmett, Patrick O. Monahan
Annals of Internal Medicine.2019; 170(5): 319. CrossRef
Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis
Kevin Selby, Emma H. Levine, Cecilia Doan, Anton Gies, Hermann Brenner, Charles Quesenberry, Jeffrey K. Lee, Douglas A. Corley
Gastroenterology.2019; 157(6): 1494. CrossRef
Quantitative fecal immunochemical tests for colorectal cancer screening
Anton Gies, Megha Bhardwaj, Christian Stock, Petra Schrotz‐King, Hermann Brenner
International Journal of Cancer.2018; 143(2): 234. CrossRef
Prevalence of functional gastrointestinal disorders in adults with systemic lupus erythematosus
M García-Carrasco, C Mendoza-Pinto, M A Autrán-Limón, E Herrera Robles, S Méndez Martínez, I Etchegaray Morales, Á Montiel Jarquín, J L Gálvez Romero, P Soto-Santillán, J Galindo-Herrera, A López-Colombo
Lupus.2018; 27(5): 788. CrossRef
Quality Metrics of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program in Korea
Dae Ho Kim, Jae Myung Cha, Min Seob Kwak, Jin Young Yoon, Young-Hak Cho, Jung Won Jeon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee
Gut and Liver.2018; 12(2): 183. CrossRef
Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas K. Rex
Gastroenterology.2017; 152(5): 1217. CrossRef
Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas K. Rex
Gastrointestinal Endoscopy.2017; 85(1): 2. CrossRef
Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
Douglas J Robertson, Jeffrey K Lee, Richard C Boland, Jason A Dominitz, Francis M Giardiello, David A Johnson, Tonya Kaltenbach, David Lieberman, Theodore R Levin, Douglas K Rex
American Journal of Gastroenterology.2017; 112(1): 37. CrossRef
Risk Factors for False Fecal Immunochemical Test Results in Colorectal Cancer Screening
Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn, Kyuyong Choi, Yoon Suk Jung
Journal of Clinical Gastroenterology.2017; 51(2): 151. CrossRef
Which Fecal Immunochemical Test Should I Choose?
Jeanette M. Daly, Yinghui Xu, Barcey T. Levy
Journal of Primary Care & Community Health.2017; 8(4): 264. CrossRef
Cancer-Type Oatp1B3 mRNA Has the Potential to Become a Detection and Prognostic Biomarker for Human Colorectal Cancer
Yuchen Sun, Manami Harada, Osamu Shimozato, Hiroaki Souda, Nobuhiro Takiguchi, Yoshihiro Nabeya, Takehiko Kamijo, Hidetaka Akita, Naohiko Anzai, Kan Chiba, Tomomi Furihata
Biomarkers in Medicine.2017; 11(8): 629. CrossRef
Screening of colorectal cancer: present and future
Marcello Maida, Fabio Salvatore Macaluso, Gianluca Ianiro, Francesca Mangiola, Emanuele Sinagra, Georgina Hold, Carlo Maida, Giovanni Cammarota, Antonio Gasbarrini, Giuseppe Scarpulla
Expert Review of Anticancer Therapy.2017; 17(12): 1131. CrossRef
Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance
Min Seob Kwak, Jae Myung Cha, Jin Young Yoon, Jung Won Jeon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee
Journal of Clinical Gastroenterology.2017; 51(9): 825. CrossRef
Accuracy of Fecal Immunochemical Tests for Colorectal Cancer
Jeffrey K. Lee, Elizabeth G. Liles, Stephen Bent, Theodore R. Levin, Douglas A. Corley
Annals of Internal Medicine.2014; 160(3): 171. CrossRef
Use of a Low Cut-Off Value for the Fecal Immunochemical Test Enables Better Detection of Proximal Neoplasia
Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jung Won Jeun, Jun Uk Lim
Digestive Diseases and Sciences.2013; 58(11): 3256. CrossRef
Performance of the Fecal Immunochemical Test Is Not Decreased by High Ambient Temperature in the Rapid Return System
Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jae Jun Park, Jung Won Jeun, Jun Uk Lim, Sang-Hyun Hwang
Digestive Diseases and Sciences.2012; 57(8): 2178. CrossRef
A comparison of qualitative and quantitative fecal immunochemical tests in the Korean national colorectal cancer screening program
Mi Jin Park, Kui Son Choi, You Kyoung Lee, Jae Kwan Jun, Hoo-Yeon Lee
Scandinavian Journal of Gastroenterology.2012; 47(4): 461. CrossRef
Clinical Features of Colorectal Cancer Detected by the National Cancer Screening Program
Dae-Do Park, Rumi Shin, Ji-Sun Kim, Heung-Kwon Oh, Seung-Yong Jeong, Kyu Joo Park, Jae-Gahb Park
Journal of the Korean Society of Coloproctology.2010; 26(6): 420. CrossRef
The Significance of Fecal Immunochemical Test to Screen for Colorectal Cancer in National Cancer Screening Program
Jun Uk Lim, Na Young Bae, Won Koung Song, Jae Myung Cha, Joung Il Lee
Intestinal Research.2010; 8(2): 126. CrossRef
False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening
Leo G.M. van Rossum, Anne F. van Rijn, Martijn G.H. van Oijen, Paul Fockens, Robert J.F. Laheij, Andre L.M. Verbeek, Jan B.M.J. Jansen, Evelien Dekker
International Journal of Cancer.2009; 125(4): 746. CrossRef
Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme
L G M van Rossum, A F van Rijn, R J F Laheij, M G H van Oijen, P Fockens, J B M J Jansen, A L M Verbeek, E Dekker
British Journal of Cancer.2009; 101(8): 1274. CrossRef
Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening Population
Leo G. van Rossum, Anne F. van Rijn, Robert J. Laheij, Martijn G. van Oijen, Paul Fockens, Han H. van Krieken, Andre L. Verbeek, Jan B. Jansen, Evelien Dekker
Gastroenterology.2008; 135(1): 82. CrossRef

11,251 View
89 Download
32 Crossref

Author index